GVHD Prevention Using CliniMACS
Feasibility Study of CD34 Selection for GVHD Prophylaxis Using the Automated CliniMACS
What will happen during the trial?
Patients eligible to be treated on this status are status post allogeneic hematopoietic stem cell transplantation for a neoplastic hematologic disorder with the need of a CD34 selected stem cell boost for graft failure or low graft function (e.g. marrow cellularity reduced per age and/or dropping donor chimerism with cytopenias and/or platelets or red blood cells transfusion requirement).
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 1
- Enrollment
- 50 patients (estimated)
- Sponsors
- University of Alabama at Birmingham
- Tags
- CD34, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Supportive
- Last Update
- 1 week ago
- SparkCures ID
- 1767
- NCT Identifier
- NCT06047886
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.